FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
Latest Stories
Telix Pharmaceutical’s proposed acquisition of a global isotope manufacturing supplier brings forth a strategically significant opportunity, although not without risks
10:00 AM
CSL’s FY26 result and FY27 guidance suggest a recovery may be underway following a long run of downgrades
Aug 19 2026
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| ACR | $0.01 | 0.00% | $0.02 | $0.01 |
|
||
| ACW | $0.06 | 0.00% | $0.07 | $0.03 |
|
||
| ADO | $0.02 | 0.00% | $0.05 | $0.01 |
|
||
| AFP | $3.44 | 0.00% | $4.13 | $2.30 |
|
||
| AGN | $0.13 |
|
$0.35 | $0.09 |
|
||
| ARX | $0.55 |
|
$0.80 | $0.50 | 37.3 |
$0.94 |
|
| ATH | $0.43 | 0.00% | $0.79 | $0.01 |
|
||
| AVH | $3.08 |
|
$3.20 | $1.00 |
$2.95 |
|
|
| BIO | $0.42 | 0.00% | $0.53 | $0.20 | 26.3 |
$0.75 |
|
| BOT | $0.02 | 0.00% | $0.17 | $0.02 |
|
||
| COV | $0.30 |
|
$0.90 | $0.29 |
|
||
| CSL | $179.65 |
|
$222.47 | $90.00 | 20.3 |
$167.673 |
|
| CUV | $8.36 |
|
$13.48 | $7.93 | 12.8 |
$10.75 |
|
| DXB | $0.24 | 0.00% | $0.67 | $0.16 |
|
||
| GSS | $0.07 | 0.00% | $0.43 | $0.05 |
$0.10 |
|
|
| IDT | $0.04 | 0.00% | $0.07 | $0.03 |
|
||
| ILA | $0.41 | 0.00% | $0.63 | $0.31 |
|
||
| IMM | $0.04 | 0.00% | $0.47 | $0.03 |
$0.06 |
|
|
| IMU | $0.04 | 0.00% | $0.46 | $0.04 |
$0.25 |
|
|
| IVX | $0.04 |
|
$0.11 | $0.03 |
|
||
| LGP | $0.07 | 0.00% | $0.15 | $0.06 |
|
||
| MAP | $0.05 | 0.00% | $0.11 | $0.04 |
$0.085 |
|
|
| MSB | $2.24 |
|
$3.31 | $1.88 | 31.6 |
$4.45 |
|
| MVP | $0.45 |
|
$0.77 | $0.37 | 112.5 |
$1.00 |
|
| MYX | $2.91 | 0.00% | $6.50 | $2.04 |
|
||
| NEU | $20.69 |
|
$23.76 | $11.00 | 51.7 |
$25.867 |
|
| NUZ | $0.08 | 0.00% | $0.17 | $0.05 |
$0.20 |
|
|
| OCC | $0.79 |
|
$1.60 | $0.67 |
$1.13 |
|
|
| OSL | $0.87 |
|
$1.81 | $0.37 |
|
||
| PAR | $0.25 | 0.00% | $0.47 | $0.14 |
$0.42 |
|
|
| PER | $0.01 | 0.00% | $0.01 | $0.00 |
|
||
| PNV | $0.97 |
|
$1.56 | $0.81 | 61.9 |
$1.21 |
|
| PYC | $2.85 |
|
$2.93 | $0.99 |
$3.55 |
|
|
| RAC | $2.02 |
|
$4.90 | $1.91 |
|
||
| RCE | $0.33 | 0.00% | $0.73 | $0.32 |
|
||
| SNT | $0.02 | 0.00% | $0.04 | $0.02 |
$0.06 |
|
|
| SPL | $0.81 | 0.00% | $0.85 | $0.22 |
|
||
| TLX | $16.01 |
|
$18.22 | $8.26 | 493.4 |
$23.138 |
|
| TRP | $0.09 |
|
$0.48 | $0.06 |
|
||
| VIT | $0.02 | 0.00% | $0.07 | $0.02 |
|
||
| ZNO | $0.05 | 0.00% | $0.18 | $0.03 |
|
3.77% Previous Stories
Strong Result, Can Telix Continue To Deliver?
Jul 22 2026
Telix has continued to outperform operationally in 2026, but future upside is increasingly dependent on pipeline execution, regulatory approvals and therapeutic progress.
CSL Challenges Pile On, Where’s The Upside?
May 13 2026
CSL surprised even the most cautious commentators with (yet again) a hefty downgrade for future earnings. Analysts are questioning where to now?
The Biotech ‘Industrialisation’
Apr 20 2026
Australian biotechs are successfully turning promising science into a scalable, repeatable, commercial system. This ‘industrialisation’ can be highly beneficial for shareholders
Telix’ Double-Product Strategy On A Roll
Apr 10 2026
Telix Pharmaceuticals’ March quarter performance beat forecasts with company management lauding the two product PSMA imaging strategy
Focus On Telix’ Guidance Post Annus Horribilis
Jan 22 2026
As Telix Pharmaceuticals turns the page on 2025, its annus horribilis, analysts remain optimistic around a potential valuation re-rating
Anti-Vaxxers & China Cloud CSL’s Future
Oct 31 2025
Falling vaccination rates in the US prompted a guidance downgrade at CSL, but was the market’s reaction excessive?
Rudi Interviewed: Diary Of A Successful Investor
Oct 20 2025
FNArena Editor Rudi Filapek-Vandyck was interviewed by Peter Switzer as the opening act in a new series titled The Diary of a Successful Investor
Is CSL Starting Its Price Recovery?
Sep 30 2025
As bruised CSL shareholders would attest to, the biotech has been challenged. Fairmont Equities’ Michael Gable reports signs of a turnaround are in place
Undervalued ASX Gems In Precision Medicine
Sep 23 2025
Flighty investors have caused share prices to fall in 2025, but MPC Markets’ Mark Gardner sees better futures ahead for two ASX-listed companies involved in cancer prevention and treatment
Earnings Result Leaves CSL Bloodied
Aug 21 2025
Uncertain Behring growth, lower vaccine sales and a controversial restructuring plan led to a post-result share price drubbing. Is it all over for CSL?